Cord Blood America Licenses Technology to AXM Pharma in China

Cord Blood America, Inc. has signed a deal licensing its umbilical cord blood technology to AXM Pharma, Inc., a China pharma and nutraceutical company. In addition to the license, Cord Blood America will provide consulting and training. In return, it will receive a 10% equity stake in AXM Pharma's stem cell subsidiary and an 8.5% royalty on all cord blood revenues. More details... Stock Symbols: (NSDQBB: CBAI) (NSDQPK: AXMP)